stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Free cash flow
CRISPR Therapeutics AG's free cash flow for fiscal 2025 was −$345.9M, compared with −$144.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$376.7M. Over the past ten years it has ranged from −$532.9M (fiscal 2022) to $457.3M (fiscal 2021); the current reading is higher than 18% of that period. CRISPR Therapeutics AG ranks 581st of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$345.9M | — |
| FY2024 | −$144.7M | — |
| FY2023 | −$269.8M | — |
| FY2022 | −$532.9M | — |
| FY2021 | $457.3M | — |
| FY2020 | −$256.7M | — |
| FY2019 | $50.0M | — |
| FY2018 | −$99.0M | — |
| FY2017 | −$77.9M | — |
| FY2016 | −$58.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$90.1M | — |
| Jun 2026 | −$84.1M | — |
| Mar 2026 | −$109.4M | — |
| Dec 2025 | −$93.1M | — |
| 41 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $85.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$121.8M |
| MANE Veradermics Incorporated compare | −$123.0M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$202.3M |
| ERAS Erasca, Inc. compare | −$252.1M |
| COGT Cogent Biosciences, Inc. compare | −$309.2M |
| CRSP CRISPR Therapeutics AG | −$376.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement